These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 34757508)

  • 21. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
    Deng R; Gibiansky L; Lu T; Agarwal P; Ding H; Li X; Kshirsagar S; Lu D; Li C; Girish S; Wang J; Boyer M; Humphrey K; Freise KJ; Salem AH; Seymour JF; Kater AP; Miles D
    Clin Pharmacokinet; 2019 Dec; 58(12):1621-1634. PubMed ID: 31209657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
    Cheung MC; Mittmann N; Owen C; Abdel-Samad N; Fraser GAM; Lam S; Crump M; Sperlich C; van der Jagt R; Prica A; Couban S; Woyach JA; Ruppert AS; Booth AM; Mandrekar SJ; McDonald G; Shepherd LE; Yen H; Chen BE; Hay AE
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):766-774. PubMed ID: 34334330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of BTK inhibitors vs bendamustine and rituximab in chronic lymphocytic leukemia patients.
    Nie J; Wu H; Wu Q; Liu Q; Liu L; Wu J
    Future Oncol; 2023 Dec; 19(38):2525-2536. PubMed ID: 38059348
    [No Abstract]   [Full Text] [Related]  

  • 25. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
    Seymour JF; Kipps TJ; Eichhorst BF; D'Rozario J; Owen CJ; Assouline S; Lamanna N; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Mellink C; Chyla B; Panchal A; Lu T; Wu JQ; Jiang Y; Lefebure M; Boyer M; Kater AP
    Blood; 2022 Aug; 140(8):839-850. PubMed ID: 35605176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse.
    Adena M; Houltram J; Mulligan SP; Todd C; Malanos G
    Pharmacoeconomics; 2014 Feb; 32(2):193-207. PubMed ID: 24442832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
    Soini E; Hautala A; Poikonen E; Becker U; Kyttälä M; Martikainen J
    Clin Ther; 2016 Apr; 38(4):889-904.e14. PubMed ID: 26970696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
    Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
    BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.
    Patel KK; Isufi I; Kothari S; Davidoff AJ; Gross CP; Huntington SF
    Blood; 2020 Oct; 136(17):1946-1955. PubMed ID: 32518952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.
    Mato AR; Roeker LE; Eyre TA; Nabhan C; Lamanna N; Hill BT; Brander DM; Barr PM; Lansigan F; Cheson BD; Singavi AK; Yazdy MS; Shah NN; Allan JN; Bhavsar EB; Rhodes J; Kennard K; Schuster SJ; Williams AM; Skarbnik AP; Goy AH; Goodfriend JM; Dorsey C; Coombs CC; Tuncer H; Ujjani CS; Jacobs R; Winter AM; Pagel JM; Bailey N; Schuh A; Shadman M; Sitlinger A; Weissbrot H; Muralikrishnan S; Zelenetz A; Kirkwood AA; Fox CP
    Blood Adv; 2019 May; 3(10):1568-1573. PubMed ID: 31101647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study.
    Mato AR; Sharman JP; Biondo JML; Wu M; Mun Y; Kim SY; Humphrey K; Boyer M; Zhu Q; Seymour JF
    Haematologica; 2022 Jan; 107(1):134-142. PubMed ID: 33327712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Lei MM; Sorial MN; Lou U; Yu M; Medrano A; Ford J; Nemec RA; Abramson JS; Soumerai JD
    Leuk Lymphoma; 2024 May; 65(5):653-659. PubMed ID: 38293753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
    Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
    J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations.
    Slot M; Niemann CU; Ehlers LH; Rotbain EC
    Blood Adv; 2023 Aug; 7(15):4186-4196. PubMed ID: 37184985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
    Zinzani PL; Flinn IW; Yuen SLS; Topp MS; Rusconi C; Fleury I; Le Dû K; Arthur C; Pro B; Gritti G; Crump M; Petrich A; Samineni D; Sinha A; Punnoose EA; Szafer-Glusman E; Spielewoy N; Mobasher M; Humphrey K; Kornacker M; Hiddemann W
    Blood; 2020 Dec; 136(23):2628-2637. PubMed ID: 32785666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.
    Schur N; Gudala K; Vudumula U; Vadapalle S; Bhadhuri A; Casanova A; Adlard N; Schwenkglenks M
    Pharmacoeconomics; 2021 May; 39(5):563-577. PubMed ID: 33791945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation of polatuzumab-bendamustine-rituximab
    Calamia M; McBride A; Abraham I
    J Med Econ; 2021 Nov; 24(sup1):14-24. PubMed ID: 34866523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.